Preimplantation genetic testing for aneuploidy versus no genetic testing in couples undergoing intracytoplasmic sperm injection for severe male infertility: multicentre, open label, randomised controlled trial.

Name: Αlpha¹ Rigor Record — Preimplantation genetic testing for aneuploidy versus no genetic testing in couples undergoing intracytoplasmic sperm injection for severe male infertility: multicentre, open label, randomised controlled trial.
Item: Preimplantation genetic testing for aneuploidy versus no genetic testing in couples undergoing intracytoplasmic sperm injection for severe male infertility: multicentre, open label, randomised controlled trial.
Rating: 100
Author: Αlpha¹

Lin X, Wu D, Zhang C, Wang L, Lu Y, Zhou P, Zhou C, Jin L, Wang L, Zhu H, Pan J, Xu C, Chen S, Gao L, Li L, Zhang S, Wu Y, Sun Y, Mol BW, Huang H

Paper source

Read full text (PMC)

Embed this Rigor badge

Αlpha¹ Rigor Review — 5★ (Exemplary), 0 critical, 0 high issues for “Preimplantation genetic testing for aneuploidy versus no genetic testing in couples undergoing intracytoplasmic sperm injection for severe male infertility: multicentre, open label, randomised controlled trial.”

Links back to this Rigor Record.

Αlpha¹ Editorial

This rigor review was examined and confirmed by Αlpha¹ Editorial · August 15, 2026

Αlpha¹ Rigor Review

Rigor Reviewed

5 / 5

Exemplary — no material problems found

Interventional Study

Critical

High-priority

How this rating was calculated▸

Started at 5★ — no deductions. Nothing the checks ran surfaced a material problem.

Model-reported confidence: highReviewer agreement: highEngine: 7.39.0Source: full text

Problems surfaced1 type

Overstated conclusions1

Conclusions that reach past what the paper's own results support — including a significance claim that no longer holds when the statistic is recomputed, and efficacy resting on an unvalidated surrogate endpoint.

Conclusions only partially backed by the presented evidenceAssessed

This Αlpha¹ Rigor Review uses AI Rigor Reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.

This is a well-conducted and transparently reported randomised controlled trial. The design is rigorous with adequate randomization, sample size justification, and pre-specified analyses. Reporting is exemplary with trial registration, CONSORT flow, and data/code sharing.

Both reviewers classified the study as interventional and agreed on all dimensions. The statistics verification covered only a subset of tests (8 of many); the rest are unverified but no errors were found. The citation check found no retracted or non-existent references.

5 major claims checked against the paper's own evidence: 1 only partially supported (evidence backs part of the claim; gaps or caveats remain); the rest adequately supported.

Efficacy claim is anchored to an adequate endpoint and a meaningful effect.

Recomputed 8 tests: 8 consistent, 0 inconsistent; 6 recomputed directly from the reported test statistics, 2 via agent-written checks.

Reporting

Eight Dimensions8 pass

The introduction cites retrospective studies suggesting PGT-A benefits in severe male infertility and notes the lack of RCTs. The rationale for the trial is clearly linked to the need for prospective evidence. Limitations of prior research are implicitly addressed by the trial's design.

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The paper establishes a clear scientific premise with prior work cited and a logical rationale for the trial.

Evidence

direct quote[Introduction, paragraph 1]

“Recent retrospective studies showed that PGT-A was associated with a lower rate of early miscarriage and an increased live birth rate per transfer in couples with severe male factor infertility. However, there are no randomised controlled trials assessing the effect of PGT-A in couples with male factor infertility problems undergoing ICSI.”